Deliver Your News to the World

Two Possible Upcoming Approvals for Spectrum Pharmaceuticals (Nasdaq:SPPI)


Pasadena, CA - 06/12/09 - BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has initiated a report on Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals (Nasdaq:SPPI) has not one but two late-stage drugs up for approval in the next four months.

While SPPI is already up 250%+ YTD, BioMedReport’s Justin Hall believes the show is just getting started.

Two Key Dates:

July 2 – The first of two big dates SPPI has regulators is scheduled for July 2. SPPI is seeking approval for their non-Hodgkin’s lymphoma (NHL) radio-immunotherapeutic, Zevalin. With approval, SPPI will market Zevalin as first-line consolidation therapy for NHL. In doing so, SPPI will finally make this effective treatment available to a greater number of patients, estimated near 28,000. Over the next 12 to 18 months, sales of Zevalin are highly likely to surge, which should translate into a big win for SPPI shareholders. I estimate Zevalin sales could reach $180 million during this time.

October 8 – The second big date is October 8. Here, SPPI is seeking approval for yet another cancer drug, Fusilev. Like Zevalin, Fusilev is also already approved by the FDA for osteosarcoma or bone cancer, which SPPI obtained in early 2008. As I recall, shares of SPPI went close to Nowhereville. That was then. In 2009, Fusilev is indicated for colorectal cancer, which affects many more Americans than osteorsarcoma. Fusilev is already approved in Europe and sold under a different trade name. Outside of the United States, sales of Fusilev, attributed to colorectal cancer, are approximately $200 million.

Investors are invited to read the full report on the company which includes company sales projections, price targets as well as a close look at Zevalin: A radio-immunotherapeutic that specifically targets and kills cancer cells, while leaving healthy cells intact.

It is available to all readers at BioMedReports.Com:

Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:

Disclosure: No positions.


About BiomedReports.Com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 FDA Approval
 FDA Decisions
 Clinical Trials
 Spectrum Pharmaceuticals

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.